Role of N-acetylcysteine and GSH redox system on total and active MMP-2 in intestinal myofibroblasts of Crohn's disease patients

Int J Colorectal Dis. 2013 Jul;28(7):915-24. doi: 10.1007/s00384-012-1632-2. Epub 2012 Dec 28.

Abstract

Purpose: Intestinal subepithelial myofibroblasts (ISEMFs)(1) are the predominant source of matrix metalloproteinase-2 (MMP-2) in gut, and a decrease in glutathione/oxidized glutathione (GSH/GSSG) ratio, intracellular redox state index, occurs in the ISEMFs of patients with Crohn's disease (CD). The aim of this study is to demonstrate a relationship between MMP-2 secretion and activation and changes of GSH/GSSG ratio in ISEMFs stimulated or not with tumor necrosis factor alpha (TNFα).

Methods: ISEMFs were isolated from ill and healthy colon mucosa of patients with active CD. Buthionine sulfoximine, GSH synthesis inhibitor, and N-acetylcysteine (NAC), precursor of GSH synthesis, were used to modulate GSH/GSSG ratio. GSH and GSSG were measured by HPLC and MMP-2 by ELISA Kit.

Results: In cells, stimulated or not with TNFα, a significant increase in MMP-2 secretion and activation, related to increased oxidative stress, due to low GSH/GSSG ratio, was detected. NAC treatment, increasing this ratio, reduced MMP-2 secretion and exhibited a direct effect on the secreted MMP-2 activity. In NAC-treated and TNFα-stimulated ISEMFs of CD patients' MMP-2 activity were restored to physiological value. The involvement of c-Jun N-terminal kinase pathway on redox regulation of MMP-2 secretion has been demonstrated.

Conclusion: For the first time, in CD patient ISEMFs, a redox regulation of MMP-2 secretion and activation related to GSH/GSSG ratio and inflammatory state have been demonstrated. This study suggests that compounds able to maintain GSH/GSSG ratio to physiological values can be useful to restore normal MMP-2 levels reducing in CD patient intestine the dysfunction of epithelial barrier.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / metabolism*
  • Adult
  • Buthionine Sulfoximine / pharmacology
  • Crohn Disease / enzymology*
  • Crohn Disease / pathology*
  • Enzyme Activation / drug effects
  • Glutathione / metabolism*
  • Glutathione Disulfide / metabolism
  • Humans
  • Intestines / pathology*
  • Intracellular Space / metabolism
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Matrix Metalloproteinase 2 / metabolism*
  • Middle Aged
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism
  • Myofibroblasts / enzymology*
  • Myofibroblasts / metabolism
  • Myofibroblasts / pathology
  • Oxidation-Reduction / drug effects
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / pharmacology
  • Tumor Necrosis Factor-alpha / pharmacology
  • Young Adult

Substances

  • Protein Kinase Inhibitors
  • Tumor Necrosis Factor-alpha
  • Buthionine Sulfoximine
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases
  • MMP2 protein, human
  • Matrix Metalloproteinase 2
  • Glutathione
  • Glutathione Disulfide
  • Acetylcysteine